Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada
- PMID: 28993862
- DOI: 10.1007/s00198-017-4218-6
Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada
Abstract
Breast cancer survivors are at high osteoporosis risk. Bone mineral density testing plays a key role in osteoporosis management. We analyzed a historical utilization of bone mineral density testing in breast cancer survivors. The utilization remained low in the 1995-2008 period. Lower socio-economic status and rural residency were associated with lower utilization.
Introduction: To evaluate the utilization of bone mineral density (BMD) testing for female breast cancer survivors aged 65+ surviving ≥ 3 years in British Columbia, Canada.
Methods: A retrospecitve population-based data linkage study. Trends in proportion of survivors with ≥ 1 BMD test for each calendar year from 1995 to 2008 were evaluated with a serial cross-sectional analysis. Associations between factors (socio-demographic and clinical) and BMD testing rates over the period 2006-2008 for 7625 survivors were evaluated with a cross-sectional analysis and estimated as adjusted prevalence ratios (PRadj) using log-binomial models.
Results: Proportions of survivors with ≥ 1 BMD test increased from 1.0% in 1995 to 10.1% in 2008. The BMD testing rate in 2006-2008 was 26.5%. Socio-economic status (SES) and urban/rural residence were associated with BMD testing rates in a dose-dependent relationship (p for trend< 0.01). Survivors with lower SES (PRadj = 0.66-0.78) or rural residence (PRadj = 0.70) were 20-30% less likely to have BMD tests, compared with survivors with the highest SES or urban residence. BMD testing rates were also negatively associated with older age (75+) (PRadj = 0.47; 95% CI = 0.42, 0.52), nursing home residency (0.05; 0.01, 0.39), recent osteoporotic fractures (0.21; 0.14, 0.32), and no previous BMD tests (0.26; 0.23, 0.29).
Conclusion: Utilization of BMD testing was low for breast cancer survivors in BC, Canada. Lower SES and rural residence were associated with lower BMD testing rates.
Implication for cancer survivors: Female breast cancer survivors, especially those with lower SES or rural residence, should be encouraged to receive BMD tests as recommended by Canadian guidelines.
Keywords: BMD; Bone mineral density test; Breast cancer; DXA; Osteoporosis; Survivors.
Similar articles
-
The effect of socioeconomic status on bone density testing in a public health-care system.Osteoporos Int. 2007 Feb;18(2):153-8. doi: 10.1007/s00198-006-0212-0. Epub 2006 Sep 20. Osteoporos Int. 2007. PMID: 17019518
-
Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study.Climacteric. 2017 Oct;20(5):491-497. doi: 10.1080/13697137.2017.1329290. Epub 2017 Jun 1. Climacteric. 2017. PMID: 28569124
-
Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer.Cancer. 2005 Oct 1;104(7):1520-30. doi: 10.1002/cncr.21335. Cancer. 2005. PMID: 16110508
-
Bone Density Screening and Re-screening in Postmenopausal Women and Older Men.Curr Osteoporos Rep. 2015 Dec;13(6):390-8. doi: 10.1007/s11914-015-0289-5. Curr Osteoporos Rep. 2015. PMID: 26408154 Free PMC article. Review.
-
Skeletal health in breast cancer survivors.Maturitas. 2017 Nov;105:78-82. doi: 10.1016/j.maturitas.2017.08.008. Epub 2017 Aug 18. Maturitas. 2017. PMID: 28838807 Review.
Cited by
-
Associations between weight-adjusted waist index and fractures: a population-based study.J Orthop Surg Res. 2023 Apr 10;18(1):290. doi: 10.1186/s13018-023-03776-8. J Orthop Surg Res. 2023. PMID: 37038167 Free PMC article.
-
A Graph-Based Approach to Identify Factors Contributing to Postoperative Lung Cancer Recurrence among Patients with Non-Small-Cell Lung Cancer.Cancers (Basel). 2023 Jul 3;15(13):3472. doi: 10.3390/cancers15133472. Cancers (Basel). 2023. PMID: 37444581 Free PMC article.
-
Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.Front Immunol. 2024 Apr 18;15:1332303. doi: 10.3389/fimmu.2024.1332303. eCollection 2024. Front Immunol. 2024. PMID: 38698843 Free PMC article.
-
Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC).Cancers (Basel). 2022 Sep 24;14(19):4633. doi: 10.3390/cancers14194633. Cancers (Basel). 2022. PMID: 36230556 Free PMC article.
-
Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.Transl Lung Cancer Res. 2025 May 30;14(5):1582-1595. doi: 10.21037/tlcr-2024-1125. Epub 2025 May 28. Transl Lung Cancer Res. 2025. PMID: 40535083 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials